Exact Mass: 365.07388000000003
Exact Mass Matches: 365.07388000000003
Found 31 metabolites which its exact mass value is equals to given mass value 365.07388000000003,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
p38 MAP Kinase Inhibitor
C20H13ClFN3O (365.07311300000003)
3-(1,3-benzothiazol-2-yl)-6-ethyl-4-oxo-4H-chromen-7-yl acetate
C20H15NO4S (365.0721750000001)
tert-Butyl 4-(4-bromo-2-cyanophenyl)piperazine-1-carboxylate
C16H20BrN3O2 (365.07388000000003)
S-1-Pyrrolidinecarboxylic acid, 2-(6-bromo-1H-benzimidazol-2-yl)-, 1,1-dimethyleth
C16H20BrN3O2 (365.07388000000003)
L-Cysteine,N-[(4-methylphenyl)sulfonyl]-S-(phenylmethyl)-
4-methoxyphenylazoformyl-phe potassium salt
C17H16KN3O4 (365.07778360000003)
Itazigrel
C18H14F3NO2S (365.06973000000005)
C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent C471 - Enzyme Inhibitor
Adenosine 5-monophosphate monohydrate
Adenosine 5'-monophosphate monohydrate is an adenosine A1 receptor agonist. Adenosine 5'-monophosphate monohydrate has significant antiviral activity against HSV-1 and HSV-2. Adenosine 5'-monophosphate monohydrate is an adenosine A1 receptor agonist. Adenosine 5'-monophosphate monohydrate has significant antiviral activity against HSV-1 and HSV-2. Adenosine 5'-monophosphate monohydrate is an adenosine A1 receptor agonist. Adenosine 5'-monophosphate monohydrate has significant antiviral activity against HSV-1 and HSV-2. Adenosine 5'-monophosphate monohydrate is an adenosine A1 receptor agonist. Adenosine 5'-monophosphate monohydrate has significant antiviral activity against HSV-1 and HSV-2.
2-[4-chloro-2-(phenylcarbonyl)phenoxy]-N-phenylacetamide
8-Carboxy-2,4,6,9-tetrahydroxy-7-methyltetracen-5-olate
[(1S)-2-[2-[(2R)-2-amino-2-carboxyethyl]selanyl-1H-imidazol-5-yl]-1-carboxyethyl]-trimethylazanium
3-methyl-1-[2-(2H-tetrazol-5-yl)ethyl]-4,6-bis(trifluoromethyl)pyrazolo[3,4-b]pyridine
tetracenomycin F1(1-)
A hydroxy monocarboxylic acid anion that is the conjugate base of tetracenomycin F1, obtained by deprotonation of the carboxy group.
6-(2-chlorophenyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine
C20H16ClN3S (365.07534060000006)
N-(2-furanylmethyl)-2-(4-oxo-6-phenyl-3-thieno[2,3-d]pyrimidinyl)acetamide
C19H15N3O3S (365.0834080000001)
4-(2,3-Dihydro-1,4-benzodioxin-3-ylmethylamino)-3-nitrobenzenesulfonamide
C15H15N3O6S (365.06815300000005)
5-(3,4-Dimethoxyphenyl)-2-phenyl-4-thieno[2,3-d][1,3]oxazinone
C20H15NO4S (365.0721750000001)
1-[(E)-[3-[(2-chloro-6-fluorophenyl)methoxy]phenyl]methylideneamino]-3-ethylthiourea
C17H17ClFN3OS (365.07648340000003)
2-(4-Bromo-3-methylphenyl)-4-[(3-methoxypropylamino)methylidene]-5-methyl-3-pyrazolone
C16H20BrN3O2 (365.07388000000003)
6-(3-chlorophenyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine
C20H16ClN3S (365.07534060000006)
1-(2-Furanylmethyl)-4-[oxo(thiophen-2-yl)methyl]-5-phenylpyrrolidine-2,3-dione
C20H15NO4S (365.0721750000001)
GYKI 52466 (dihydrochloride)
C17H17Cl2N3O2 (365.06977620000004)
GYKI 52466 dihydrochloride is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC50 values of 7.5 and 11μM, respectively. GYKI 52466 dihydrochloride has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 dihydrochloride can be used in Parkinson's disease research[1][2].
5,5-dichloro-1-(2,4-dihydroxy-5,6-dimethoxypyridin-3-yl)-2,4-dimethylhexan-1-one
C15H21Cl2NO5 (365.07967160000004)
(2s,4s,5r)-5,6-dichloro-1-(2,4-dihydroxy-5,6-dimethoxypyridin-3-yl)-2,4-dimethylhexan-1-one
C15H21Cl2NO5 (365.07967160000004)
5,6-dichloro-1-(2,4-dihydroxy-5,6-dimethoxypyridin-3-yl)-2,4-dimethylhexan-1-one
C15H21Cl2NO5 (365.07967160000004)